MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
27.67
+1.60
+6.14%
Pre Market: 27.50 -0.17 -0.61% 04:00 07/08 EDT
OPEN
26.30
PREV CLOSE
26.07
HIGH
27.80
LOW
26.10
VOLUME
1
TURNOVER
0
52 WEEK HIGH
31.77
52 WEEK LOW
13.06
MARKET CAP
3.46B
P/E (TTM)
-1317.6190
1D
5D
1M
3M
1Y
5Y
1D
Arcutis gets FDA review for Zoryve 0.05% label expansion
Seeking Alpha · 58m ago
Arcutis' ZORYVE Crème SNDA Accepted By FDA For Infants With Atopic Dermatitis
NASDAQ · 2h ago
Arcutis Biotherapeutics's SNDA For ZORYVE Cream 0.05% Gets FD Acceptance
NASDAQ · 3h ago
Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants
Dow Jones · 3h ago
Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA
TipRanks · 3h ago
FDA accepts Arcutis sNDA for Zoryve cream use in infants with atopic dermatitis
PUBT · 3h ago
FDA Accepts Supplemental New Drug Application For Arcutis Biotherapeutics' ZORYVE Cream 0.05%
Benzinga · 3h ago
ARCUTIS BIOTHERAPEUTICS - FDA SETS PDUFA TARGET ACTION DATE OF FEBRUARY 23, 2027 FOR ZORYVE CREAM 0.05% SNDA
Reuters · 3h ago
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.